Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Position Lowered by California Public Employees Retirement System

California Public Employees Retirement System cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,725 shares of the medical equipment provider’s stock after selling 3,228 shares during the period. California Public Employees Retirement System owned approximately 0.18% of Lantheus worth $7,485,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Foundry Partners LLC acquired a new position in Lantheus during the fourth quarter valued at $4,582,000. Handelsbanken Fonder AB grew its stake in Lantheus by 3.1% in the fourth quarter. Handelsbanken Fonder AB now owns 13,200 shares of the medical equipment provider’s stock valued at $818,000 after purchasing an additional 400 shares in the last quarter. Verdence Capital Advisors LLC acquired a new position in Lantheus in the 4th quarter worth about $262,000. Kornitzer Capital Management Inc. KS acquired a new position in Lantheus in the 4th quarter worth about $1,048,000. Finally, Martin Capital Advisors LLP increased its position in Lantheus by 2.3% in the 4th quarter. Martin Capital Advisors LLP now owns 11,679 shares of the medical equipment provider’s stock worth $724,000 after purchasing an additional 267 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

LNTH opened at $75.53 on Friday. The stock’s 50 day moving average price is $62.67 and its two-hundred day moving average price is $62.83. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $100.85. The firm has a market capitalization of $5.18 billion, a P/E ratio of 16.28 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold 94,545 shares of company stock worth $6,169,936 in the last 90 days. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research reports. Mizuho upped their target price on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. B. Riley increased their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. JMP Securities reissued a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday. Finally, Truist Financial increased their price objective on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a report on Friday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $103.14.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.